This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ultram ER

Valeant Pharmaceuticals International, Inc.

Drug Names(s): tramadol hydrochloride extended-release, Ralivia

Description: Ultram ER is a once-daily, extended-release tablet formulation of tramadol.

Ultram ER uses Biovail's Smartcoat technology to produce an extended-release tablet that provides patients pain control over a 24-hour period.

Deal Structure: Biovail and Johnson & Johnson
In January 2008, Biovail entered into an exclusive supply agreement with Janssen, a division of Johnson & Johnson, for the marketing and distribution of Biovail's once-daily, extended-release formulation of tramadol hydrochloride in 86 countries in two regions - Central and Eastern Europe/Middle East and Latin America.

Under the terms of this agreement, which has a 10-year term, Biovail will manufacture and supply once-daily extended-release tramadol hydrochloride tablets in dosage strengths of 100mg, 200mg and 300mg to Janssen at contractually determined prices. Janssen affiliates will be responsible for all related promotional costs, as well as all regulatory filings and the management of the regulatory approvals process.

Partners: Johnson & Johnson


Ultram ER News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug